A dozen deaths in a phase III trial apparently is not a good sign. Lilly suspended the current trial on its melanoma drug, tasisulam after just such a result. This follows failures with teplizumab for diabetes, Bydureon for diabetes, and semagacesta for Alzheimer's in just the past four months. See Fierce Biotech. What do you do for an encore from here?
CEO John Lechleiter earlier in the year was crowing about Lilly's strong pipeline and used that as one of his main reasons the company was NOT going to be involved in the acquisiiton frenzy -- at least for a major-sized company. Now what? Anybody got the M&A team on speed dial?
Posted by Bruce Lehr December 14th 2010.
Comments